Journal
HUMAN MOLECULAR GENETICS
Volume 25, Issue 13, Pages 2853-2861Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddw141
Keywords
-
Funding
- SMA Trust
- Anatomical Society
- AxonomiX Consortium
- Euan MacDonald Centre for Motor Neurone Disease Research
- Muscular Dystrophy UK
- Wellcome Trust
Ask authors/readers for more resources
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein, primarily affecting lower motor neurons. Recent evidence from SMA and related conditions suggests that glial cells can influence disease severity. Here, we investigated the role of glial cells in the peripheral nervous system by creating SMA mice selectively overexpressing SMN in myelinating Schwann cells (Smn(-/-);SMN2(tg/0);SMN1(SC)). Restoration of SMN protein levels restricted solely to Schwann cells reversed myelination defects, significantly improved neuromuscular function and ameliorated neuromuscular junction pathology in SMA mice. However, restoration of SMN in Schwann cells had no impact on motor neuron soma loss from the spinal cord or ongoing systemic and peripheral pathology. This study provides evidence for a defined, intrinsic contribution of glial cells to SMA disease pathogenesis and suggests that therapies designed to include Schwann cells in their target tissues are likely to be required in order to rescue myelination defects and associated disease symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available